GlassScriptPhysician profile
Pamela Ingram
NPI 1508193855
$5,960.16
in general payments reported to CMS, 2019-2025
57 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $735 · 2022: $1,120 · 2023: $1,435 · 2024: $1,329 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,104.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $564.59 | 2021-2025 | |
| Janssen Biotech, INC. | $444.91 | 2021-2025 | Rybrevant, Erleada, Darzalex |
| Incyte Corporation | $422.24 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $296.29 | 2021-2025 | Ojjaara, Shingrix, Blenrep |
| Takeda Pharmaceuticals U.S.A., INC. | $275.14 | 2021-2025 | Fruzaqla, Iclusig, Ninlaro |
| Abbvie INC. | $270.84 | 2021-2025 | |
| Pfizer INC. | $263.33 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $237.35 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Eisai INC. | $236.13 | 2021-2025 | |
| Amgen INC. | $192.31 | 2021-2023 | Lumakras, Blincyto, Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $161.38 | 2021-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $157.02 | 2021-2025 | Lynparza, Calquence |
| Sumitomo Pharma America, INC. | $128.85 | 2023-2025 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $127.63 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genzyme Corporation | $123.05 | 2021-2025 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $115.72 | 2021-2025 | Tecentriq, Itovebi |
| Aveo Pharmaceuticals, INC. | $104.68 | 2022-2024 | Fotivda |
| Array Biopharma INC | $95.40 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $92.75 | 2021-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $92.31 | 2022-2025 | Onivyde |
| Celgene Corporation | $89.48 | 2021-2024 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $89.46 | 2022-2025 | Injectafer |
| Alexion Pharmaceuticals, INC. | $88.72 | 2021-2025 | Ultomiris |
| Exelixis INC. | $88.60 | 2024-2025 | Cabometyx |
| Beigene USA, INC. | $87.02 | 2021-2024 | Brukinsa, Tevimbra |
| Seagen INC. | $85.30 | 2021-2023 | Tukysa |
| Taiho Oncology, INC. | $76.81 | 2023-2025 | |
| Astellas Pharma US INC | $65.71 | 2021-2025 | Vyloy, Xtandi |
| Emd Serono, INC. | $65.09 | 2021-2024 | Bavencio |
| Adc Therapeutics America, INC. | $62.05 | 2022-2023 | |
| Blueprint Medicines Corporation | $59.58 | 2021-2023 | Ayvakit |
| Pharmacosmos Therapeutics INC. | $59.58 | 2023 | Monoferric |
| Jazz Pharmaceuticals INC. | $58.99 | 2021-2023 | |
| Gilead Sciences, INC. | $45.97 | 2023-2024 | Trodelvy |
| Geron Corporation | $43.69 | 2025 | Rytelo |
| Lilly USA, LLC | $36.40 | 2023-2025 | Verzenio, Jaypirca |
| Pharmaessentia USA Corporation | $34.34 | 2022-2023 | Besremi |
| Myovant Sciences INC. | $32.86 | 2022 | |
| Karyopharm Therapeutics INC. | $31.47 | 2021-2022 | |
| Tersera Therapeutics LLC | $29.13 | 2021-2023 | Xermelo |
| Sobi, INC | $29.10 | 2023-2025 | |
| Stemline Therapeutics INC. | $28.82 | 2023 | Orserdu |
| Beone Medicines USA, INC. | $28.79 | 2025 | Tevimbra, Brukinsa |
| Mirati Therapeutics, INC. | $28.20 | 2023 | Krazati |
| Myriad Genetic Laboratories, INC. | $21.52 | 2023 | Bracanalysis Cdx |
| Syndax Pharmaceuticals, INC. | $20.78 | 2025 | Revuforj |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.64 | 2021 | |
| G1 Therapeutics, INC. | $17.95 | 2022 | |
| Springworks Therapeutics, INC. | $17.64 | 2025 | Ogsiveo |
| Coherus Oncology, INC. | $17.25 | 2022 | |
| Morphosys, US INC. | $16.21 | 2022 | |
| Novocure INC. | $15.00 | 2025 | Optune Lua (Novottf-200t) |
| Foundation Medicine, INC. | $14.55 | 2022 | |
| Acrotech Biopharma INC. | $13.39 | 2022 | |
| Tactile Systems Technology INC | $13.26 | 2022 | |
| Acceleron Pharma, INC. | $13.04 | 2021 | |
| Puma Biotechnology, INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.